Implications for metabolic disturbances in myelodysplastic syndromes.

doi:10.1053/j.seminhematol.2024.11.004

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Implications for metabolic disturbances in myelodysplastic syndromes.

Seminars in hematology - 1 Dec 2024

McGraw Kathy L, Larson Daniel R

Abstract excerpt

The Myelodysplastic Syndromes (MDS) are heterogeneous stem cell malignancies clinically characterized by bone marrow dysplasia, peripheral blood cytopenias, and a high risk for transformation to acute myeloid leukemia. In early stages of disease, differentiation defects and maturation blocks result in deficient hematopoiesis. In higher risk disease, unrestricted proliferation of immature blast cells leads to...

Topics

Myelodysplastic Syndromes
Humans
Mutation
Hematopoietic Stem Cells
Inflammation
Hematopoiesis

Source

Open in PubMed Open full text

Identifiers

PMID: 39603905
DOI: 10.1053/j.seminhematol.2024.11.004
PMCID: PMC11646176

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics